Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

This study has been completed.
Information provided by:
Alcon Research Identifier:
First received: April 23, 2007
Last updated: July 28, 2008
Last verified: July 2008

The purpose of thie study is to compare the safety and IOP-lowering efficacy of AL-37807 Ophthalmic Solution 0.05%, 0.1% and 0.2% dosed QD AM to Xalatan dosed QD PM and Vehicle in patients with open-angle glaucoma or ocular hypertension

Condition Intervention Phase
Open-Angle Glaucoma
Ocular Hypertension
Drug: Xalatan
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Mean IP Change from Baseline

Estimated Enrollment: 150
Study Start Date: March 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Open-angle glaucoma
  • ocular hypertension

Exclusion Criteria:

- VA worse than 0.60

  Contacts and Locations
Please refer to this study by its identifier: NCT00465621

United States, Georgia
Atlanta, Georgia, United States, 30342
Sponsors and Collaborators
Alcon Research
Study Director: Theresa Landry Alcon Research
  More Information

No publications provided Identifier: NCT00465621     History of Changes
Other Study ID Numbers: C-06-10
Study First Received: April 23, 2007
Last Updated: July 28, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Alcon Research:
Open-angle glaucoma
ocular hypertension

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions processed this record on April 14, 2014